Pharmacodynamic effects of cilostazol versus clopidogrel in stented patients under proton pump inhibitor co-administration: the ACCEL-PARAZOL study.
نویسندگان
چکیده
AIM Proton pump inhibitor (PPI) therapy has been shown to attenuate the antiplatelet effects of clopidogrel. The aim of this study was to compare the antiplatelet effects of cilostazol versus clopidogrel in patients co-administered a PPI. METHODS We enrolled PPI-naïve stented patients treated with standard clopidogrel and aspirin therapy for at least six months (n=100). The patients were randomly assigned to receive either cilostazol at a dose of 100mg twice daily (CILO group) or clopidogrel at a dose of 75mg daily (CLPD group) in addition to lansoprazole (30mg daily). The platelet aggregation (PA) determined using light transmittance aggregometry and the platelet reactivity index (PRI) obtained using a vasodilator-stimulated phosphoprotein phosphorylation assay were measured before randomization and at the 14-day follow-up visit. The primary endpoint was the PRI value at follow-up. RESULTS At follow-up, the CLPD group showed similar values of PRI as the CILO group (66.9±14.0% vs. 63.1±14.1%; mean difference: 3.9%; 95% confidence interval of difference: -1.7% to 9.4%; p=0.174). However, the 6μg/mL collagen- and 0.5mg/mL arachidonic acid-induced PA values in the CLPD group were higher than those observed in the CILO group (mean differences: 9.8% to 11.1%; all p values <0.001). CYP2C19 loss-of-function allele carriage was the major contributing factor associated with the PRI level in the absence of lansoprazole treatment (with a gene-dose effect); this association was not observed in the subjects receiving lansoprazole co-administration in the CLPD group. CONCLUSIONS During lansoprazole co-administration, cilostazol treatment achieves a more favorable platelet function profile than clopidogrel therapy. The use of combination treatment with cilostazol and aspirin deserves further attention with respect to the management of stable stented patients requiring PPI co-administration.
منابع مشابه
Circulation: Cardiovascular Interventions Topic Review Circulation: Cardiovascular Interventions Editors’ Picks: Most Important Papers in Antiplatelet Therapy
A growing body of evidence has shown a broad variability in interindividual pharmacodynamic response profiles to the platelet inhibitor clopidogrel, and patients with reduced platelet inhibition have an increased risk of recurrent atherothrombotic events. Numerous factors may contribute to poor clopidogrel response. Among these, that secondary to a drug interaction with the proton pump inhibito...
متن کاملCirculation: Cardiovascular Interventions Topic Review Circulation: Cardiovascular Interventions Editors’ Picks: Most Important Papers in Antiplatelet Therapy
A growing body of evidence has shown a broad variability in interindividual pharmacodynamic response profiles to the platelet inhibitor clopidogrel, and patients with reduced platelet inhibition have an increased risk of recurrent atherothrombotic events. Numerous factors may contribute to poor clopidogrel response. Among these, that secondary to a drug interaction with the proton pump inhibito...
متن کاملCirculation: Cardiovascular Interventions Topic Review Circulation: Cardiovascular Interventions Editors’ Picks: Most Important Papers in Antiplatelet Therapy
A growing body of evidence has shown a broad variability in interindividual pharmacodynamic response profiles to the platelet inhibitor clopidogrel, and patients with reduced platelet inhibition have an increased risk of recurrent atherothrombotic events. Numerous factors may contribute to poor clopidogrel response. Among these, that secondary to a drug interaction with the proton pump inhibito...
متن کاملCirculation: Cardiovascular Interventions Topic Review Circulation: Cardiovascular Interventions Editors’ Picks: Most Important Papers in Antiplatelet Therapy
A growing body of evidence has shown a broad variability in interindividual pharmacodynamic response profiles to the platelet inhibitor clopidogrel, and patients with reduced platelet inhibition have an increased risk of recurrent atherothrombotic events. Numerous factors may contribute to poor clopidogrel response. Among these, that secondary to a drug interaction with the proton pump inhibito...
متن کاملCirculation: Cardiovascular Interventions Topic Review Circulation: Cardiovascular Interventions Editors’ Picks: Most Important Papers in Antiplatelet Therapy
A growing body of evidence has shown a broad variability in interindividual pharmacodynamic response profiles to the platelet inhibitor clopidogrel, and patients with reduced platelet inhibition have an increased risk of recurrent atherothrombotic events. Numerous factors may contribute to poor clopidogrel response. Among these, that secondary to a drug interaction with the proton pump inhibito...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Journal of atherosclerosis and thrombosis
دوره 21 11 شماره
صفحات -
تاریخ انتشار 2014